Oncology Corporate Profile
SA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology, which have the potential to generate safe and effective immunologic responses with a known mechanism of action. Synthetic long peptides are broadly applicable to multiple targets and ideally suited for monotherapy, as essential components in combination with conventional cancer treatments, and with novel immunomodulators such as Nivolumab. SLP® immunotherapies are designed to fully harness and direct the body's own defenses towards fighting the disease.
11/3/2016 11:42 am
(Reuters) Nov 2, 2016 - Cancer drugmakers are cutting prices to ensure their medicines are used routinely on Britain's National Health Service, following the overhaul of a cancer drug funding scheme, with Japan's Eisai the latest to win approval.
10/11/2016 12:12 pm
(Bloomberg) Oct 10, 2016 - Ono Pharmaceutical Co. shares dropped in Japan trading after its partner Bristol-Myers Squibb Co. released study results for its immune-based therapy Opdivo that fell short of already low expectations in a lung cancer trial that studied wider use of the drug.
10/10/2016 06:24 am
(Bloomberg) Oct 9, 2016 - Bristol-Myers Squibb Co.’s immune-based therapy Opdivo fell short of already low expectations in study results that throw into question whether the drug can help lung-cancer patients who’ve just been diagnosed.
9/26/2016 11:24 am
(Seattle Times/Associated Press) Sept 26, 2016 - Two lawsuits ended in jury verdicts worth $127 million. Two others were tossed out by a judge who said there wasn’t reliable evidence that the talc in Johnson & Johnson’s iconic baby powder causes ovarian cancer. So who’s right? And is baby powder safe?
9/19/2016 11:52 am
(Reuters) Sept 17, 2016 - Novartis's investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease versus a placebo, the Swiss company said on Saturday, citing a new analysis of a late-stage trial.
9/16/2016 11:49 am
(STAT/Pharmalot) Sept 15, 2016 - In response to the intensifying outrage over the cost of medicines, a bipartisan group of lawmakers Thursday introduced a bill that would require drug makers to justify their pricing and provide a breakdown of their costs before raising prices on certain products by more than 10 percent.
9/15/2016 12:05 pm
(PharmaTimes [UK]) Sept 15, 2016 - The European Commission has stamped its approval on the use of Eisai's Kisplyx to treat advanced kidney cancer.
9/6/2016 10:51 am
(pharmaphorum [UK]) Sept 5, 2016 - Eisai may have to sell its Halaven (eribulin) at rock-bottom prices in its new advanced liposarcoma use in Germany after a cost-effectiveness body found it offered “no additional benefit” compared with standard care.
8/30/2016 11:23 am
(Medscape Medical News) Aug 29, 2016 - The commonly used chemotherapy agent capecitabine can leave many patients without fingerprints, but the effect is temporary.
8/25/2016 06:57 am
(STAT) Aug 24, 2016 - It’s a dilemma more and more cancer patients will face as genetic testing becomes part of everyday health care: When a DNA test indicates low risk of a tumor spreading, but traditional tests show a high risk, which do you believe?
8/11/2016 02:00 pm
[at noodls] - Pursuant to the Rules of the Ljubljana Stock Exchange, Ljubljana, Sava Reinsurance Company, d.d., Ljubljana hereby announces the following: Sava Reinsurance Company, d.d., (hereinafter: Company) received ...
8/9/2016 11:23 am
(Reuters) Aug 9, 2016 - Japan's Eisai Co said on Tuesday the U.S. Food and Drug Administration had confirmed that there was sufficient data to start Phase III studies of a drug it is co-developing to treat early Alzheimer's disease.
8/2/2016 11:15 am
(PharmaTimes [UK]) Aug 2, 2016 - Patients with an advanced form thyroid cancer may have to wait three years for NHS access to Eisai's Lenvima in England, after the drug was left out of the newly launched Cancer Drugs Fund.
7/29/2016 11:17 am
(news@JAMA) July 27, 2016 - Presidential elections rarely turn on debates over policy. They are typically influenced much more by the state of the economy, what is happening in the world, and the personal characteristics of the candidates.
7/26/2016 11:13 am
(Yahoo! Finance) July 26, 2016 - Halozyme Therapeutics, Inc. announced today that Eisai Inc. has dosed the first patient in a collaborative phase 1b/2 clinical trial to assess whether Eisai's eribulin mesylate (HALAVEN®) in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) can improve overall response rate (ORR) – the proportion of women that have a predefined reduction in tumor burden – as compared with eribulin alone as a therapy in women with advanced or metastatic, High-Hyaluronan (HA) HER2-negative breast cancer.
7/12/2016 07:19 am
(PharmaTimes [UK]) July 12, 2016 - Patients with thyroid cancer could be waiting three years for access to Eisai's Lenvima because the drug was left out of the re-launched Cancer Drugs Fund (CDF) and NICE guidance is not to be published until 2018.
7/8/2016 11:13 am
(Reuters) July 7, 2016 - Japan's Eisai said on Friday it would consider all options, including possible legal action, to fight delays in Britain's healthcare system that prevent patients from accessing one of its drugs to treat a rare form of cancer.
5/24/2016 12:10 pm
(NPR/Shots blog) May 24, 2016 - In his recent book, The Finest Traditions of My Calling, Dr. Abraham Nussbaum, 41, makes the case that doctors and patients alike are being shortchanged by current medical practices that emphasize population-based standards of care rather than individual patient needs and experiences.
5/16/2016 07:03 am
(Eisai) May 13, 2016 - Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved LENVIMA®(lenvatinib), the company's multiple receptor tyrosine kinase inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (aRCC) who were previously treated with an anti-angiogenic therapy.
5/12/2016 12:17 pm
(New York Times Magazine) May 12, 2016 - In an era of rapidly proliferating, precisely targeted treatments, every cancer case has to be played by ear.
5/5/2016 11:35 am
(PharmaTimes [UK]) May 5, 2016 - Patients with a type of advanced tissue sarcoma called liposarcoma living in the European Union can now potentially get access to Eisai’s Halaven after regulators waved through the drug.
4/25/2016 11:39 am
(NYU Langone) Apr 22, 2016 - Melanoma, mesothelioma are the focus of first joint studies.
4/20/2016 12:30 pm
(Morningstar) Apr 20, 2016 - Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Avinash Desai, MD, as Vice President, Americas Oncology Medical Affairs for the Oncology Business Group (OBG).
4/5/2016 07:07 am
(PharmaTimes [UK]) Apr 4, 2016 - Eisai’s breast cancer drug Halaven could soon be available in Europe to treat liposarcoma, after regulatory advisors backed expanding its use.
4/4/2016 11:29 am
(4-traders) Apr 2, 2016 - The study will evaluate two-compartment dosimetry (normal tissue and tumour absorbed dose) in hepatocellular carcinoma patients in interventional oncology in an effort towards a more personalised approach to Y radioembolisation therapy for liver cancer patients.
4/1/2016 11:27 am
(Pharmaceutical Business Review) Apr 1, 2016 - Eisai has signed an agreement to transfer the exclusive global development and commercialization rights, excluding Japan and Asia, to its cancer drug candidate E7777 to Dr. Reddy’s Laboratories.
2/15/2016 02:05 pm